Download Biosimilar and Interchangeable Biologics: Strategic Elements by Sarfaraz K. Niazi PDF

By Sarfaraz K. Niazi

What’s the care for Biosimilars?

Biosimilars are gaining momentum as new protein healing applicants that could support fill a necessary want within the healthcare undefined. The organic medicines are produced by means of recombinant DNA expertise that permits for large-scale construction and an total aid time in expenditures and improvement.

Part of a two-volume set that covers various features of biosimilars, Biosimilars and Interchangeable Biologics: Strategic parts explores the strategic making plans part of biosimilar medications and goals concerns surrounding biosimilars which are associated with criminal issues. This comprises valuable patents and highbrow estate, regulatory pathways, and matters approximately affordability on an international scale. It addresses the complexity of biosimilar items, and it discusses the usage of biosimilars and similar organic medicinal drugs in increasing international markets.

Of particular curiosity to practitioners, researchers, and scientists within the biopharmaceutical undefined, this quantity examines the technology, expertise, finance, legality, ethics, and politics of biosimilar medications. It considers strategic making plans components that come with an total figuring out of the historical past and the present prestige of the paintings and technology of biosimilars, and it offers particular descriptions of the felony, regulatory, and advertisement features. The e-book additionally provides an international approach on the way to construct, take to marketplace, and deal with the subsequent new release of biosimilars all through their existence cycle.

Show description

Read or Download Biosimilar and Interchangeable Biologics: Strategic Elements PDF

Best biotechnology books

Sequencing of Proteins and Peptides

Even if there's a carrying on with excessive point of task in direct reports on protein basic constructions, the requirement for partial sequences has supplied a huge impetus for the advance and dissemination of hugely delicate innovations. whereas preserving the nonetheless acceptable bold foundation of the unique quantity, this Revised variation displays the shift in the direction of using extra refined automatic high-performance chromatographic strategies.

Reversible Protein Acetylation

A complete overview of contemporary paintings on chromatin and non-histone proteins, this publication arises from the interactions of a multidisciplinary crew of scientists enthusiastic about the research of acetylation. This sector of analysis opens up new and intriguing percentages for drug layout, and so the ultimate chapters within the ebook study the various power purposes within the remedy of varied ailments.

Pharmacognosy and Pharmaco-biotechnology, Second Revised and Expanded Edition

Comprising of the 2 disciplines that supply this e-book its name, this revised and up-to-date re-creation takes the data of gear and using common medicinal drugs as its significant instructing schedule. protecting a wide spectrum of issues, it is going to be compatible for higher point classes in utilized chemistry, phytochemistry, pharmacognosy, pharmaceutical chemistry and various fields of biotechnology.

Crystalline Bacterial Cell Surface Proteins (Biotechnology Intelligence Unit)

Crystalline Bacterial phone floor Proteins assembles info on the understanding of the prevalence, constitution, chemistry, genetics, meeting, functionality, and alertness strength of S-layers. The chapters are designed to face self sufficient of one another and supply an entire survey of the several themes in S-layer learn.

Additional info for Biosimilar and Interchangeable Biologics: Strategic Elements

Example text

Currently, biological drugs command a market of about $200 billion, half of which is in the United States. S. markets. For example, antibodies and fusion proteins used for the treatment of symptoms of rheumatoid arthritis may cost between $10K and $30K per year, with very high copays, making their penetration and availability limited. The same holds true for cytokines like pegylated filgrastim and most anticancer drugs. The cost of biological drugs used in the treatment of cancer can run much higher.

This heterogeneity in labeling biosimilars itself points to the complexity of understanding by different regulatory agencies about the exact nature of these products. It is anticipated that over time, “biosimilars” would become the default definition for the products that are introduced once the patents expire on the gene sequences that are associated with specific molecules. The differentiation of products from being therapeutically interchangeable to biosimilar had its roots in the size of active molecules; compared with synthetic small molecules, biologics are 100–1000 times larger in size, having several hundred amino acids (average molecular weight of 150 per amino acid), which are biochemically joined together in a defined sequence by peptide bonds to form a polypeptide.

Chapter 6: ROW regulatory guidance The EMA and FDA have brought forth their own guidelines for gaining regulatory approval of a biosimilar product with clarity, but the rest of the world has either adopted this guidance, for example, Japan, or adopted modified forms of these guidelines. In some countries, these guidelines are still being developed, and other countries treat biosimilars like small molecule drugs or as new biologics. This chapter provides an extensive study of these guidelines, relative comparisons of the various entry points, and suggests the changes about to become worldwide in the regulatory landscape of biosimilars.

Download PDF sample

Rated 4.36 of 5 – based on 20 votes